Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab plus daratumumab versus daratumumab-based triplets in relapsed or refractory multiple myeloma
2023-503441-55-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 2, randomised trial of teclistamab, daratumumab, pomalidomide, bortezomib and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: PFS. Planned start Oct 2021; status: authorised.
02
Drugs
teclistamabdaratumumabpomalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-503441-55-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503441-55-00.